An observational study in Implantable Cardioverter Defibrillator (ICD), sponsored by AZ Sint-Jan AV. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by AZ Sint-Jan AV · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. The main goal of the study is to keep track of:
The BELIEVE registry (BELgian registry of Implanted EV-ICDs to Evaluate parameters and complications) is a multicenter, observational registry designed to gather real-world data on the use of extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium. This new generation of ICD technology offers the potential advantages of both subcutaneous (S-ICD) and transvenous (TV-ICD) devices, with the lead placed under the sternum. This position enables pacing capabilities and more accurate arrhythmia detection while aiming to minimize lead-related complications seen in previous ICD systems.
Given the relatively recent introduction of EV-ICDs, it is essential to monitor their performance and clinical outcomes in routine clinical settings. While initial trials have demonstrated feasibility and safety, real-world data are crucial for understanding long-term efficacy, complication rates, therapy effectiveness, device longevity, and overall patient outcomes. The BELIEVE registry was therefore established to support this need, offering a structured framework to follow patients over time and improve clinical practice related to EV-ICDs.
The registry is both retrospective and prospective, non-randomized, and will include all patients in Belgium who undergo (or have undergone) an EV-ICD implantation-regardless of whether the procedure was successful. Participating centers will aim to enroll an initial cohort of 100 patients over a 4-year period, although the number of patients and study duration may be extended. The total planned study period is 15 years, with patients followed throughout the life of their device.
Inclusion criteria are broad: participants must be at least 18 years old, have had or be scheduled for an EV-ICD implantation (even if unsuccessful), and must provide informed consent. Patients who did not undergo any part of the implantation procedure are excluded.
Data will be collected at baseline, during the procedure, and during scheduled follow-up visits (at 1-3 months, 6 months, and then at least annually). Information will include demographic and clinical characteristics, medical history, device data, arrhythmia detection, therapy delivery, programming changes, complications, and patient-reported outcomes.
AZ Sint-Jan AV is the lead sponsor of 60 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients who underwent or will undergo an EV-ICD implantation in Belgium, whether successful or not, can be included in this registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of delivered therapies (ATP and shocks)
Total number of therapies delivered by the device, including antitachycardia pacing and shocks (Unit: count)
Time frame: Lifetime of the device (up to 15 years)
Proportion of delivered therapies that were appropriate
Percentage of therapies delivered by the device that were adjudicated as appropriate (i.e., delivered for true ventricular arrhythmia).
Time frame: Lifetime of the device (up to 15 years)
Proportion of delivered therapies that were successful
Percentage of therapies delivered by the device that successfully terminated the targeted ventricular arrhythmia.
Time frame: Lifetime of the device (up to 15 years)
Tracking procedural and device-related complications
Tracking procedural and device-related complications during the lifetime of the device
Time frame: Lifetime of the device (up to 15 years)
Change in sensing amplitude over time
Change in device-recorded sensing amplitude (in mV) from implantation to follow-up visits.
Time frame: Lifetime of the device (up to 15 years)
Change in pacing threshold over time
Change in pacing threshold (in Volt) measured during device follow-up from implantation to 15 years.
Time frame: Lifetime of the device (up to 15 years)
Change in lead impedance over time
Change in lead impedance (in Ohm) from implantation to 15 years of follow-up.
Time frame: Lifetime of the device (up to 15 years)
Change in battery longevity estimates over time
Change in estimated battery longevity (in years) as reported by the device at each follow-up visit.
Time frame: Lifetime of the device (up to 15 years)
Accuracy of arrhythmia detection by the device
Proportion of arrhythmia episodes correctly classified by the device (%)
Time frame: Lifetime of the device (up to 15 years)
Summary of device reprogramming
Summary of every device reprogramming including reason for changes
Time frame: Lifetime of the device (up to 15 years)
Number of participants with major adverse cardiac events (MACE)
Number of participants experiencing major adverse cardiac events, including cardiovascular death, hospitalization for heart failure, myocardial infarction, or stroke.
Time frame: Lifetime of the device (up to 15 years)
Number of participants with device-related infections
Number of participants with infections requiring antibiotic treatment or device/system extraction.
Time frame: Lifetime of the device (up to 15 years)
Number of participants reporting device-related complaints
Number of participants reporting device-related symptoms or complaints (e.g., inappropriate shocks, pain at device site).
Time frame: Lifetime of the device (up to 15 years)
Started Sep 2025 (actual). Primary completion is estimated for Jul 2040, 177 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AZ Sint-Jan AV